Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate (ALIGHT-COPD)
This study has been completed.
Sponsor:
Almirall, S.A.
Collaborator:
Forest Laboratories
Information provided by:
Almirall, S.A.
ClinicalTrials.gov Identifier:
NCT01078623
First received: March 1, 2010
Last updated: November 5, 2010
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in patients with stable, moderate to severe COPD.
Every treatment period is 14-days long and there is a 7-days wash-out period in between them. The trial starts with a run in phase of 10 to 17-days duration and it ends up with a follow up contact 14-days after last treatment dose.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease |
Drug: Aclidinium and Formoterol Drug: Placebo Drug: Formoterol Drug: Aclidinium |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy, Safety and Tolerability of Two Fixed-Dose Combinations of Aclidinium Bromide With Two Doses of Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo All Administered Twice Daily in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease Patients. |
Resource links provided by NLM:
MedlinePlus related topics:
COPD (Chronic Obstructive Pulmonary Disease)
Drug Information available for:
Formic acid
Formoterol fumarate
Formoterol
Arformoterol Tartrate
Aclidinium bromide
U.S. FDA Resources
Further study details as provided by Almirall, S.A.:
Primary Outcome Measures:
- FEV1 AUC 0-12h [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- morning pre-dose FEV1 and morning peak FEV1 [ Time Frame: Day 14 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 120 |
| Study Start Date: | February 2010 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Formoterol
Formoterol
|
Drug: Formoterol
Formoterol dose
|
|
Placebo Comparator: Placebo
Placebo
|
Drug: Placebo
Placebo control
|
|
Experimental: Aclidinium and Formoterol (I)
Fixed dose combination
|
Drug: Aclidinium and Formoterol
Fixed Dose (I)
|
|
Experimental: Aclidinium and Formoterol (II)
Fixed dose combination
|
Drug: Aclidinium and Formoterol
Fixed dose (II)
|
|
Experimental: Aclidinium
Aclidinium
|
Drug: Aclidinium
Aclidinium dose
|
Eligibility| Ages Eligible for Study: | 40 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult male or non-pregnant, non-lactating female aged between 40 and 80 years old, both inclusive.
- Patient with a clinical diagnosis of stable moderate to severe COPD according to the GOLD classification
- Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.
- Patient whose FEV1 at the Screening Visit measured between 10-15 minutes post inhalation of 400 mcg of salbutamol is 30% FEV1 <80% of the predicted normal value (i.e., 100 x Post-salbutamol < FEV1/ Predicted FEV1 must be < 80% and ≥ 30%).
- Patient whose FEV1/FVC at the Screening Visit measured between 10-15 minutes post inhalation of 400 mcg of salbutamol is < 70% (i.e., 100 x Post-salbutamol FEV1 /FVC < 70%).
- Patient who is eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained.
- Patient whose COPD symptoms and FEV1 values at the time of randomisation are stable compared to the Screening Visit, according to the investigator's medical judgment
Exclusion Criteria:
- History or current diagnosis of asthma or exercise-induced bronchospasm.
- Clinically significant respiratory conditions at the time of Inform Consent signature
- Hospitalisation due to COPD exacerbation within the previous 3 months.
- Signs of a COPD exacerbation or respiratory infection (including the upper respiratory tract) within the previous 6 weeks.
- Patient who has a resting systolic blood pressure ≥ 200 mmHg, a resting diastolic blood pressure ≥ 120 mmHg or a resting heart rate ≥ 105 bpm at screening visit.
- Clinically significant cardiovascular conditions
- Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction.
- Presence of narrow-angle glaucoma.
- QTc [calculated according to Bazett's formulae (QTc=QT/RR1/2) above 470 milliseconds in the ECG performed at Screening Visit,
- Patient who does not maintain regular day/night, waking/sleeping cycles
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01078623
Locations
| Czech Republic | |
| Almirall Investigational Sites#3 | |
| Hlucin, Czech Republic, 748 21 | |
| Almirall Investigational Sites#1 | |
| Praha, Czech Republic, 130 00 | |
| Almirall Investigational Sites#2 | |
| Praha, Czech Republic, 150 06 | |
| Almirall Investigational Sites#5 | |
| Rokycany, Czech Republic, 337 01 | |
| Germany | |
| Almirall Investigational Sites#3 | |
| Berlin, Germany, 14059 | |
| Almirall Investigational Sites#5 | |
| Berlín, Germany, 10717 | |
| Almirall Investigational Sites#2 | |
| Donaustauf, Germany, 93093 | |
| Almirall Investigational Sites#6 | |
| Lübeck, Germany, 23538 | |
| Almirall Investigational Sites#4 | |
| Schwerin, Germany, 19055 | |
| Hungary | |
| Almirall Investigational Sites#2 | |
| Komarom, Hungary, 2900 | |
| Almirall Investigational Sites#3 | |
| Komlo, Hungary, 7300 | |
| Almirall Investigational Sites#1 | |
| Szarvas, Hungary, 5540 | |
| Poland | |
| Almirall Investigational Sites#1 | |
| Krakow, Poland, 31-501 | |
| Almirall Investigational Sites#2 | |
| Krakow, Poland, 31-023 | |
| Almirall Investigational Sites#4 | |
| Lublin, Poland, 20-718 | |
| Almirall Investigational Sites#3 | |
| Olawa, Poland, 55-200 | |
| Romania | |
| Almirall Investigational Sites#4 | |
| Bucuresti, Romania, 12384 | |
| Almirall Investigational Sites#9 | |
| Bucuresti, Romania, 11025 | |
| Almirall Investigational Sites#13 | |
| Bucuresti, Romania, 22328 | |
| Almirall Investigational Sites#10 | |
| Cluj, Romania, CLUJ | |
| Almirall Investigational Sites#1 | |
| Constanta, Romania, 900002 | |
| Almirall Investigational Sites#7 | |
| Deva, Romania, 330084 | |
| Almirall Investigational Sites#6 | |
| Iasi, Romania, 700115 | |
| Almirall Investigational Sites#3 | |
| Iasi, Romania, 700305 | |
| Almirall Investigational Sites#14 | |
| Iasi, Romania, 700381 | |
| Almirall Investigational Sites#8 | |
| Oradea, Romania, 410176 | |
| Almirall Investigational Sites#5 | |
| Tg Mures, Romania, 540072 | |
| Almirall Investigational Sites#12 | |
| Timisoara, Romania, 0 | |
Sponsors and Collaborators
Almirall, S.A.
Forest Laboratories
More Information
Additional Information:
No publications provided
| Responsible Party: | Estrella Garcia, Almirall |
| ClinicalTrials.gov Identifier: | NCT01078623 History of Changes |
| Other Study ID Numbers: | M/40464/26 |
| Study First Received: | March 1, 2010 |
| Last Updated: | November 5, 2010 |
| Health Authority: | Hungary: National Institute of Pharmacy Czech Republic: State Institute for Drug Control Germany: Federal Institute for Drugs and Medical Devices Poland: Ministry of Health Romania: National Authority for Scientific Research |
Keywords provided by Almirall, S.A.:
|
Bronchitis Chronic Emphysema |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Bromides Formoterol Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Adrenergic beta-2 Receptor Agonists |
Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents |
ClinicalTrials.gov processed this record on May 16, 2013